Tonix Pharmaceuticals Receives MCDC Grant to Advance TNX-801 Vaccine Against Smallpox and Mpox
Key Insights
Tonix Pharmaceuticals (search) has secured funding from the Medical CBRN Defense Consortium to develop TNX-801, a recombinant horsepox virus-based vaccine targeting both mpox (search) and smallpox (search).
The single-dose vaccine demonstrates improved tolerability compared to traditional vaccinia-based vaccines, with preclinical studies showing effectiveness against monkeypox (search) amid ongoing global outbreaks.
The grant will support comprehensive market analysis, target market identification, and commercialization planning for both government and private sectors.
Tonix Pharmaceuticals (search) Holding Corp. (NASDAQ: TNXP) has received a significant grant from the Medical CBRN Defense Consortium (MCDC) to advance the development of its TNX-801 vaccine candidate for smallpox (search) and mpox (search). The MCDC, which supports the U.S. government in developing medical countermeasures against chemical, biological, radiological, and nuclear threats, will provide funding to accelerate the vaccine's path to market.
TNX-801 is a recombinant horsepox virus-based live vaccine designed to provide protection against both smallpox (search) and mpox (search) with a single dose. The vaccine candidate has shown promising results in preclinical studies, demonstrating effectiveness against monkeypox (search) while offering potential advantages over existing vaccines.
Innovative Vaccine Technology
The TNX-801 vaccine represents a significant advancement in orthopoxvirus vaccine technology. Unlike older vaccinia-based vaccines that have been associated with adverse events, TNX-801 is designed to offer improved tolerability while maintaining robust efficacy.
Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (search), explained, "TNX-801 is engineered to provide long-term protection with a single dose administration, which addresses important logistical challenges in vaccine deployment, especially in regions with limited healthcare infrastructure."
Preclinical data has shown that TNX-801 generates protective immunity against monkeypox (search), suggesting potential broad utility against orthopoxviruses. This is particularly relevant given the ongoing outbreaks of clade I mpox (search) in several countries, which has raised concerns about global public health preparedness.
Strategic Market Development
The MCDC grant will specifically support comprehensive market analyses, target market identification, and commercialization planning for both government and private sectors. This strategic approach acknowledges the dual-market potential for vaccines against biodefense threats.
"This funding will enable us to develop robust commercialization strategies for TNX-801, ensuring that the vaccine can be effectively deployed when needed," said a spokesperson for Tonix Pharmaceuticals (search). "We're examining innovative delivery methods that could improve patient compliance, ease of use, and tolerability."
The company's manufacturing capabilities are already positioned to support the development of TNX-801. Tonix owns a GMP-capable advanced manufacturing facility in Dartmouth, Maryland, which was purpose-built to manufacture TNX-801. The facility's GMP suites are ready to be reactivated in case of a national or international emergency.
Broader Portfolio Development
The TNX-801 program is part of Tonix's broader portfolio of infectious disease countermeasures and CNS therapeutics. The company is preparing to submit a New Drug Application (NDA) to the FDA for TNX-102 SL for the management of fibromyalgia (search), for which the FDA has granted Fast Track designation.
Additionally, Tonix recently secured a contract worth up to $34 million over five years from the U.S. Department of Defense's Defense Threat Reduction Agency to develop TNX-4200, a small molecule broad-spectrum antiviral targeting CD45 (search).
Public Health Significance
The development of TNX-801 comes at a critical time in global public health. Recent mpox (search) outbreaks have highlighted the need for effective countermeasures against orthopoxviruses. The World Health Organization has documented cases of clade I mpox, which is associated with higher mortality rates than the clade II variant that caused the 2022 global outbreak.
Public health experts emphasize that having multiple vaccine options is essential for pandemic preparedness. "Different vaccine platforms offer varying advantages in terms of production scalability, storage requirements, and suitability for different populations," noted an infectious disease specialist familiar with orthopoxvirus vaccines. "Adding TNX-801 to the arsenal of available vaccines would strengthen our preparedness posture."
Future Directions
As Tonix advances TNX-801 with support from the MCDC grant, the company will continue to generate data on the vaccine's safety, immunogenicity, and efficacy. The development pathway will likely include further preclinical studies and eventual clinical trials to demonstrate the vaccine's potential in humans.
The company's dual-market approach—targeting both government biodefense stockpiling and conventional commercial markets—reflects the evolving landscape of vaccines against potential pandemic pathogens, where public and private interests increasingly align.
With its state-of-the-art infectious disease research facility in Frederick, Maryland, and manufacturing capabilities in Dartmouth, Tonix is positioned to advance TNX-801 from research through potential commercialization, addressing an important gap in biodefense and public health preparedness.